Immunogenicity and Safety Study of a Quadrivalent Meningococcal Conjugate Vaccine When Co-administered With Routine Pediatric Vaccines in Healthy Infants and Toddlers in Europe

Inclusion Criteria: * Aged ≥ 42 to ≤ 89 days on the day of the first study visit * Healthy infants as determined by medical history, physical examination and judgment of the Investigator * Informed consent form has been signed and dated by the parent(s) or other legally acceptable representative * Subject and parent/legally acceptable representative were able to attend all scheduled visits and to comply with all study procedures * Covered by health insurance according to local regulations Exclusion Criteria: * Participated at the time of study enrollment (or in the 4 weeks preceding the first study vaccination) or planned participation during the study period in another clinical study investigating a vaccine, drug, medical device, or medical procedure * Received any vaccine in the 4 weeks preceding the first study vaccination or planned receipt of any vaccine in the 4 weeks before and/or following any study vaccination except for influenza vaccination and rotavirus vaccination, which may be received at a gap of at least 2 weeks before or 2 weeks after any study vaccines. This exception included monovalent pandemic influenza vaccines and multivalent influenza vaccines. This exclusion criterion did not apply to subjects in Finland, Sweden or Poland who planned to receive the licensed rotavirus vaccine concomitantly with study vaccines at study vaccination visits V1 and V2. * Received or planned to receipt during the study period vaccination against meningococcal disease with…